Fibroid Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Uterine fibroids (leiomyomas or myomas) are benign smooth muscle tumours arising from the myometrium (uterine wall). They are the most common benign neoplasm of the female reproductive tract, affecting up to 70–80% of women by the age of 50. Most fibroids are asymptomatic and discovered incidentally on pelvic ultrasound; symptomatic fibroids are a leading cause of gynaecological morbidity, accounting for approximately one-third of all hysterectomies performed globally.

Fibroids are classified by location: submucosal fibroids (beneath the endometrium, projecting into the uterine cavity) cause the most significant bleeding and fertility problems; intramural fibroids (within the uterine wall) are the most common; subserosal fibroids (projecting outward from the uterine surface) cause bulk symptoms; pedunculated fibroids hang from a stalk. Fibroid growth is oestrogen- and progesterone-dependent, explaining their peak prevalence in reproductive years and regression after menopause.

Treatment choice is guided by symptom severity, fibroid size and location, the patient's reproductive goals, age, and general medical status. Asymptomatic fibroids require no treatment. Medical options aim to reduce fibroid volume and control symptoms (particularly heavy menstrual bleeding) without surgery. Interventional radiology (uterine artery embolisation) and focused ultrasound ablation are minimally invasive alternatives. Surgical options range from uterus-preserving myomectomy to definitive hysterectomy. The treatment landscape has expanded significantly over the past decade, giving women more options and control over their care.

Heavy menstrual bleeding (HMB) is the most common symptom of fibroids, particularly submucosal and large intramural fibroids. HMB causes anaemia in up to 40% of symptomatic fibroid patients, leading to fatigue, reduced quality of life, and impaired work capacity. Treatment targets both haemostasis and fibroid volume reduction. Pelvic pain and pressure — including dysmenorrhoea (painful periods), pelvic heaviness, urinary frequency from bladder compression, and constipation from rectal pressure — affect women with large or multiple fibroids.

Fibroid-related infertility and recurrent miscarriage are critical indications for treatment, particularly in women planning pregnancy. Submucosal fibroids distort the uterine cavity and impair embryo implantation. Intramural fibroids above 4–5 cm can reduce IVF success rates. Myomectomy — surgical removal of fibroids — is the treatment of choice for women who wish to preserve fertility. Symptoms during pregnancy, including pain from fibroid degeneration, placenta praevia, malpresentation, and obstructed labour, may also necessitate treatment planning.

Women with symptomatic fibroids — heavy bleeding causing anaemia, significant pelvic pain or pressure, urinary symptoms, or reproductive difficulties — are candidates for treatment. Asymptomatic fibroids generally do not require treatment unless rapidly growing or causing significant organ distortion. The choice between medical, interventional, and surgical treatment depends on the woman's age, reproductive intentions, fibroid characteristics (number, size, location), and preference.

Contraindications are treatment-specific. GnRH agonists are used short-term (typically 3–6 months) due to hypoestrogenic side effects including bone density reduction. Uterine artery embolisation (UAE) should not be used in women who wish to maintain fertility as its effects on uterine function and subsequent pregnancy are not fully characterised. Myomectomy is the preferred surgical option for women who wish to conceive; hysterectomy is appropriate for women who have completed their family and desire definitive treatment.

Medical options include the levonorgestrel intrauterine system (LNG-IUS, e.g., Mirena), which reduces menstrual bleeding by up to 85% and can be inserted in the clinic without general anaesthesia (it does not reduce fibroid size). Combined oral contraceptives and progestins reduce bleeding but have variable effects on fibroid volume. GnRH agonists (goserelin, leuprorelin) induce a reversible menopausal state, reducing fibroid size by 40–60% and stopping menstrual bleeding; they are used pre-operatively to reduce fibroid bulk and correct anaemia. Relugolix combination therapy (an oral GnRH receptor antagonist) offers sustained fibroid volume reduction without hypoestrogenic side effects of prolonged GnRH agonist therapy.

Minimally invasive procedures include uterine artery embolisation (UAE) — an interventional radiology procedure cutting off fibroid blood supply, causing progressive shrinkage (35–55% volume reduction) — and MRI-guided focused ultrasound (MRgFUS), which ablates fibroid tissue without incisions. Surgical options include hysteroscopic myomectomy (for submucosal fibroids), laparoscopic myomectomy (for intramural and subserosal fibroids), robotic-assisted laparoscopic myomectomy, and open abdominal myomectomy for large or multiple fibroids. Hysterectomy is the definitive treatment eliminating all fibroids permanently. Shared decision-making between the patient and specialist ensures the chosen modality aligns with individual anatomy, comorbidities, risk tolerance, and personal goals. A formal consultation with a board-certified specialist, review of pre-treatment imaging or investigation results, and multidisciplinary team input for complex cases are standard practice before finalising the treatment plan.

The LNG-IUS achieves 85–90% reduction in menstrual blood loss in most women and significantly improves quality of life within 3–6 months of insertion. GnRH agonists produce amenorrhoea in most patients within 4–6 weeks, rapidly correcting anaemia and reducing fibroid volume before surgery. UAE achieves significant symptom improvement in 85–90% of women at 12 months, with menstrual blood loss reduced by 70–80%. Patient satisfaction rates are high, with 85–90% of women expressing satisfaction at 1–2 years.

Laparoscopic myomectomy achieves excellent symptom relief while preserving the uterus: 80–90% of women report significant reduction in menstrual bleeding and pain. Pregnancy rates after laparoscopic myomectomy for submucosal and large intramural fibroids are significantly improved. Hysterectomy provides complete and permanent resolution of fibroid symptoms in 100% of cases, with the vast majority of women reporting improved quality of life.

UAE carries risks of post-embolisation syndrome (fever, pelvic pain, nausea occurring in up to 30% of cases in the first few days, self-limiting), non-target embolisation (rare, less than 1%), amenorrhoea due to ovarian infarction (in approximately 1–3% of women, more common in those over 45), and expulsion of submucosal fibroids (4–5%). UAE is not recommended for women wishing to conceive, as subsequent pregnancy outcomes are less predictable than after myomectomy.

Myomectomy carries risks of significant intraoperative bleeding (fibroid vascularity is high), conversion from laparoscopic to open surgery (5–10%), uterine rupture in subsequent pregnancy (approximately 1% for intramural myomectomy), and fibroid recurrence (up to 30% at 5 years). Hysterectomy involves risks of haemorrhage, ureteral and bladder injury (less than 1% with experienced surgeons), venous thromboembolism, wound infection, and irreversible loss of fertility. GnRH agonists cause menopausal side effects (hot flushes, vaginal dryness, insomnia, mood changes) and bone density reduction with prolonged use.

After UAE, patients are typically hospitalised for 1–2 nights for pain management. Full recovery takes 1–2 weeks; most women return to work within 7–10 days. Pelvic MRI at 3–6 months confirms fibroid infarction and volume reduction. After laparoscopic myomectomy, recovery takes 1–2 weeks; patients wishing to conceive are advised to wait 3–6 months before attempting pregnancy to allow uterine healing. Open myomectomy requires 4–6 weeks recovery.

After hysterectomy, recovery varies by approach: laparoscopic/robotic hysterectomy patients typically return to light activities within 2–4 weeks; open (abdominal) hysterectomy requires 4–6 weeks. Hormone replacement therapy (HRT) is offered to women under 50 who undergo concurrent bilateral salpingo-oophorectomy to prevent premature menopause. All women undergoing major fibroid surgery should have haemoglobin checked at 6 weeks to ensure anaemia has resolved.

In the United States, laparoscopic myomectomy costs USD 12,000–25,000 including hospital and anaesthesia fees; UAE costs USD 8,000–15,000; total laparoscopic hysterectomy costs USD 15,000–30,000. GnRH agonist medications (monthly depot injections) cost USD 400–800 per injection. These procedures are often covered by insurance when medically indicated.

Medical tourism offers substantial savings. Laparoscopic myomectomy at JCI-accredited hospitals in India costs USD 2,000–5,000 — a saving of 70–80%. UAE in India costs USD 1,500–3,500. Thailand and Turkey offer comparable quality at similar prices. Women travelling abroad for fibroid treatment should confirm the gynaecologist's laparoscopic surgery credentials, the hospital's blood banking capacity, and post-discharge follow-up arrangements. Patients are advised to obtain itemised cost estimates from multiple providers and verify insurance coverage or national health system entitlements before proceeding. Medical tourism at accredited hospitals in India, Thailand, Turkey, or Mexico can reduce total procedure costs by 50–80% compared to US or UK pricing, with internationally trained specialists and comparable clinical outcomes for elective procedures.

For women approaching menopause, expectant management (watchful waiting with symptomatic management of bleeding using tranexamic acid, NSAIDs, or the LNG-IUS) is a reasonable strategy, as fibroids typically shrink after menopause due to oestrogen withdrawal. This avoids surgery and its associated risks in women who will soon become menopausal naturally.

For women with heavy bleeding from fibroids who wish to avoid hysterectomy, endometrial ablation — destruction of the uterine lining using heat or cold energy — can significantly reduce menstrual loss. It is appropriate only for small or no submucosal fibroids and is contraindicated if the woman wishes to conceive. Transcervical fibroid ablation (radiofrequency systems) is a newer hysteroscopic approach ablating submucosal and intramural fibroids from within the uterine cavity, offering a day-procedure uterus-preserving alternative.